ALT
#2809
Altimmune, Inc. - Common Stock
3.1 3 USD
-0.03%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
Year Range
Daily Change
-3.40%
Monthly Change
+4.33%
6 month change
-25.48%
Year Change
-15.86%
Previous Close
3.2 4
Open
3.0 9
Low
3.0 8
High
3.1 3
Volume
745
Financials
- Market Capitalization 608.84 M
- Employee 57
- Founded 1997
- CEO Jerry Durso
- Website www.altimmune.com
- Headquarter Delaware, United States
- FIGI BBG000FXML90
- Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-3.61
Price to sales ratio
7 757.46
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 2775 |  SLN Silence Therapeutics Plc - American Depository Share | 13.46 USD | +0.07% | +1.43% | +17.86% | +163.92% | 635.94 M USD | ||
| 2794 |  AUTL Autolus Therapeutics plc - American Depositary Shares | 2.34 USD | -0.85% | -2.90% | +61.38% | +48.10% | 622.82 M USD | ||
| 2822 |  ARVN Arvinas, Inc. - Common Stock | 9.17 USD | -0.76% | -2.13% | +12.10% | -1.40% | 599.59 M USD | ||
| 2826 |  SPRY ARS Pharmaceuticals, Inc. - Common Stock | 5.89 USD | -2.32% | +6.90% | +5.18% | -36.05% | 585.74 M USD |
Frequently asked questions about Altimmune, Inc. Common Stock
What is the Altimmune, Inc. Common Stock stock price today?
The current price of Altimmune, Inc. Common Stock (ALT) is 3.13. Over the past 24 hours, the stock has changed by -3.40%. Follow the ALT chart for real-time price dynamics.
What is the stock ticker of Altimmune, Inc. Common Stock?
Altimmune, Inc. Common Stock trades under the ticker ALT. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Altimmune, Inc. Common Stock stock going up?
ALT has changed by +0.64% over the last week, +4.33% over the last month, and -15.86% over the last year. Review the chart to see whether the current move is part of a broader trend.
What is the market capitalization of Altimmune, Inc. Common Stock?
Altimmune, Inc. Common Stock currently has a market capitalization of 608.84 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.
What were Altimmune, Inc. Common Stock earnings last quarter?
Last quarter, Altimmune, Inc. Common Stock reported earnings of -0.12 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.
What was Altimmune, Inc. Common Stock revenue for the last quarter?
Altimmune, Inc. Common Stock reported quarterly revenue of -22 K. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.
What was Altimmune, Inc. Common Stock net income for the last quarter?
Altimmune, Inc. Common Stock reported net income of -22.82 M for the last quarter. The previous quarter showed -22.56 M, which means net income changed by -1.16%.
How many employees does Altimmune, Inc. Common Stock have?
As of the latest available data, Altimmune, Inc. Common Stock has 57 employees. Workforce size can provide additional context about the company's scale and operations.
What is Altimmune, Inc. Common Stock EBITDA?
Altimmune, Inc. Common Stock EBITDA is -26.98 M, and its EBITDA margin is 122.61 K%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Altimmune, Inc. Common Stock stock?
You can buy Altimmune, Inc. Common Stock (ALT) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Altimmune, Inc. Common Stock stock?
Investing in Altimmune, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the ALT chart and related analysis on metatrader.com as part of your research.